Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Discov Med. 2012 Oct;14(77):283–288.

Table 1.

Associations (P≤0.05) Between Cancer Risk, and DNA Adduct Value in (the 25% of) Individuals with the Highest Adduct Levels Compared with Those Having the Lowest Adduct Levels.

Carcinogen:
DNA Adduct Source
Organ:
DNA Adduct Measurement
Organ:
Cancer Site
Method of DNA Adduct Measurement RRa or OR for Cancer Risk Reference
4-ABP liver liver IHCb 6.5 Wang et al., 1998
PAHs liver liver IHC 3.9 Chen, 2002
PHIP breast breast IHC 4.0 Zhu et al., 2003
PAHs blood colon ELISAc 2.8 Gunter et al. 2007
PAHs blood lung ELISA 7.7 Tang et al., 1995
AFB1 urine liver HPLCd 9.1 Qian et al., 1994
“Bulky”e blood stomach 32-P-postlabelling 2.2 Agudo et al., 2012
“Bulky” blood colon 32P-postlabelling 2.3 Agudo et al.. 2012
“Bulky” blood bladder 32P-postlabelling 4.1 Peluso et al., 1998
“Bulky” blood
(current smokers)
lung 32P-postlabclling 3.0 Tang et al., 2001
“Bulky” blood
(current smokers)
lung 32P-postlabclling 2.0 Peluso et al., 2005
“Bulky” blood
(current smokers)
lung 32P-postlabelling 1.6 Veglia et al., 2008
a

RR = Relative Risk or OR = Odds Ratio in the 25% of individuals having the highest DNA adduct levels compared with those having the lowest DNA adduct levels. All values shown arc statistically significant to p≤0.05.

b

IHC = Immunohistochemistry.

c

ELISA = Enzyme linked immunosorbent assay.

d

HPLC = High performance liquid chromatography.

e

“Bulky” DNA adducts isolated by 32P-postlabeling arc typically stable, high-molecular weight DNA adducts that are formed from PAHs, aromatic amines, nitroaromatics, hormones, aflatoxins, and/or other hydrophobic DNA-binding agents (see examples in Figure 1).